| Identification | Back Directory | [Name]
SRI-37330 HCl | [CAS]
2322245-49-6 | [Synonyms]
SRI37330 HCl
SRI-37330 HCl
SRI 37330 HCl
SRI37330 hydrochloride
SRI-37330 hydrochloride
SRI 37330 hydrochloride | [Molecular Formula]
C16H20ClF3N4O2S | [MOL File]
2322245-49-6.mol | [Molecular Weight]
424.87 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, away from moisture | [solubility ]
DMSO:62.5(Max Conc. mg/mL);147.1(Max Conc. mM) | [form ]
Solid | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Description]
SRI-37330 hydrochloride is a novel inhibitor of TXNIP expression, decreasing glucagon secretion and action and blocking hepatic glucose output, reversing obesity- and STZ-induced diabetes and hepatic steatosis. | [Uses]
SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research[1]. | [in vivo]
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) hydrochloride decreases glucagon secretion and action and blocks hepatic glucose output[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) hydrochloride is well tolerated in male C57BL/6J mice[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) hydrochloride reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice[1].
| [target]
SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. | [References]
[1] Thielen LA, et al. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8. DOI:10.1016/j.cmet.2020.07.002 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
| Company Name: |
xinguokeji
|
| Telephone: |
13120711461 |
| Website: |
|
|